Durham biotech startup Tellus secures $35M Series A to advance treatment for babies in the NICU
RTP neonatal care company Tellus Therapeutics has successfully closed a $35 million Series A funding round to advance its drug candidates.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
